Navigation Links
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
Date:12/23/2011

quired to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; our response to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, of the Marketing Authorization Application, or MAA, for Qnexa; the results of external studies to assess the teratogenic risk of topiramate; results of the REMS or cardiovascular outcomes for obesity advisory meetings; the outcome of the second advisory committee meeting for Qnexa; the impact, if any, of the agreement by one of our competitors with an obesity compound to conduct or complete a cardiovascular outcomes study pre-approval; impact on future sales based on specific indication and contraindications contained in the label and extent of the REMS, distribution and patient access program; the FDA's response to the NDA filed for avanafil; our ability to successfully commercialize or establish a marketing partnership for avanafil or our partner's ability to obtain regulatory approval to manufacture and adequately supply avanafil for commercial use; our history of losses and variable quarterly results; substantial competition; risks related to the failure to protect our intellectual property and litigation in which we may become involved; uncertainties of government or third party payer reimbursement; our reliance on sole source suppliers; our limited sales and marketing efforts and our reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative par
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
7. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
8. VIVUS Announces Sale of MUSE Assets to Meda
9. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
11. VIVUS to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 According to ... & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), ... QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global ... Oligonucleotide Synthesis Market is expected to reach $1,712.1 ... growing at a CAGR of 9.8% from 2014 ...
(Date:8/29/2014)... 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... intends to release its financial results for the fiscal ... after market trading ends on Tuesday, September 9, 2014. ... for 4:30 p.m. U.S. EDT on Tuesday, September 9, ... review the Company,s financial results, commercial partnerships, and future ...
(Date:8/29/2014)... 2014 Research and Markets has ... Drugs Market 2014-2018" report to their offering. ... condition that results in demyelination, axonal transection, and neurodegeneration. ... response by the immune system, which targets neurons within ... debilitating disease in which the damage of the myelin ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... , MOUNTAIN VIEW, Calif. , Jan. ... system solutions to acute healthcare facilities, today announced results for its fourth ... results: Revenue for the fourth quarter of 2009 was $54.7 ... quarter of 2009, and down $7.4 million or 11.9% from ...
... , ORLANDO, Fla. , Jan. 28 ... advisor Hal Broxmeyer , Ph.D., on becoming the 2010 President ... President of such an important organization as ASH is a tremendous ... work that Dr. Broxmeyer has performed, and we are deeply honored ...
Cached Medicine Technology:Omnicell Announces Fourth Quarter and Full-Year 2009 Results 2Omnicell Announces Fourth Quarter and Full-Year 2009 Results 3Omnicell Announces Fourth Quarter and Full-Year 2009 Results 4Omnicell Announces Fourth Quarter and Full-Year 2009 Results 5Omnicell Announces Fourth Quarter and Full-Year 2009 Results 6Omnicell Announces Fourth Quarter and Full-Year 2009 Results 7Omnicell Announces Fourth Quarter and Full-Year 2009 Results 8Omnicell Announces Fourth Quarter and Full-Year 2009 Results 9Omnicell Announces Fourth Quarter and Full-Year 2009 Results 10Omnicell Announces Fourth Quarter and Full-Year 2009 Results 11Omnicell Announces Fourth Quarter and Full-Year 2009 Results 12Omnicell Announces Fourth Quarter and Full-Year 2009 Results 13Omnicell Announces Fourth Quarter and Full-Year 2009 Results 14CORD:USE Cord Blood Bank Congratulates Team Member Hal Broxmeyer, Ph.D., on his Election as President of the American Society of Hematology 2CORD:USE Cord Blood Bank Congratulates Team Member Hal Broxmeyer, Ph.D., on his Election as President of the American Society of Hematology 3
(Date:8/30/2014)... plant-based medication commonly used to treat gout, before ... reducing potential complications from this type of surgery, ... adverse effects, according to a study published by ... early online to coincide with its presentation at ... complications after cardiac surgery include postpericardiotomy syndrome (the ...
(Date:8/30/2014)... 30, 2014 "My niece developed a ... at any moment, her fever might get worse," said ... me well aware of how she was doing, I ... ALARM to continuously monitor a child's temperature. The unit ... This ensures that prompt medical care can be given, ...
(Date:8/30/2014)... 30, 2014 Bringing forth the great ... announces the Labor Day discount on all SEO ... get the complete services related to internet marketing. Their ... Writers, and others do have a deep understanding for ... in their work and since the inception, they have ...
(Date:8/30/2014)... "I had a handicapped friend who could not walk along ... Wetumpka, Ala. "In order to help her be able to ... up with a way for her to use her crutches ... patent-pending Deezers to allow crutches to be used on uneven ... or canes at the beach. The device reduces the risk ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
Breaking Medicine News(10 mins):Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... that are not often discussed like cross-dressing, homosexuality and ... international film festival on gender and sexuality, which attracted ... ,Brought together by the Public Service Broadcasting ... and UNESCO, the four-day festival at the India Habitat ...
... Love revealed that she chants as she decides what to ... ,Chanting is used by many Buddhists celebrities including Tina ... ,Love reportedly wrote on her website: "I chanted two ... go." ,She is deciding between having a private ...
... Spanish Wine Fair (Fenavin) here, India has said it ... in production if a strong element of "price sensitivity" ... necessarily mean selling the cheapest wine," Subhash Arora, president ... three-day fair Wednesday. ,India already has a ...
... at least six years away for talented actress Kangana Ranaut but ... she wants in Mr.Right! ,"I'm going to get ... years to find Mr. Right," Kangana told IANS. ... has to be a white-collar professional like a doctor or a ...
... to have found a treatment, which could block the action ... cancer. ,The enzyme PTP1B appears to fuel tumor ... in treating the disease. About 40 percent of human breast ... this enzyme. ,Michel Tremblay and colleagues at McGill ...
... school bullying has decided to give more power to school ... ,The Prime Minister will announce this move at a meet ... ,Yet, critics of the Prime Minister like the ... this is nothing new. ,New South Wales Education ...
Cached Medicine News:Health News:Film Festival on Gender Sexuality Draws Crowds 2Health News:India is Uncorking Its Wine Market: Expert 2Health News:Gentle, Real, Well-mannered - Kangana's Mr. Right 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: